Buchang Pharmaceuticals

Shandong Buchang Pharmaceuticals Co., Ltd. ("Buchang Pharmaceuticals" for short) was established in 2001 and completed its shareholding system reform in 2012. It passed the IPO review of the Issuance Examination Committee of the CSRC in July 2016 and was successfully listed on November 18, 2016.Over the course of 20 years of development, Buchang Pharmaceuticals has built a clear development strategy: "Focus on major diseases and cultivate large varieties." With patented proprietary Chinese medicines as its core, the company is committed to the modernization of traditional Chinese medicine (TCM), fully leveraging the important role of TCM in the field of cardiovascular and cerebrovascular diseases, which are considered "major and chronic diseases." This has led to a three-dimensional product portfolio that focuses on the cardiovascular and cerebrovascular market, covers the traditional strengths of proprietary Chinese medicines, emphasizes major diseases, and nurtures large varieties. Based on the theory of "treating the brain and heart together," Buchang Pharmaceuticals has developed and cultivated three exclusive patented products: Naoxintong Capsules, Wenxin Granules, and Danhong Injection, with treatment scopes covering common cardiovascular and cerebrovascular diseases such as stroke, arrhythmia, insufficient blood supply, and ischemic infarction. As a leading enterprise in patented prescription TCM, its main products also have strong competitiveness in the fields of gynecological medication, diabetes, and oncology. The gynecological drug Honghe Fuyuan Cleansing Solution is a national Class III new TCM drug and an exclusive product of the company. The company has also achieved product coverage in pediatrics, anti-tumor, urology and digestion, bone joints, and respiratory systems, with popular products including Qianlieshutong Capsules, Ganshuang, Kelu Oral Liquid, and Xiashuangju Granules.The company can currently produce various dosage forms such as capsules, granules, and injections. In September 2018, Buchang officially announced its transformation from a marketing-driven model to a product-driven model, transitioning towards becoming a technology-oriented company; expanding from proprietary Chinese medicines into biopharmaceuticals, chemical drugs, medical devices, and internet-based healthcare across the entire industry; and evolving from localization in China to globalization, steadily realizing its biopharmaceutical strategic plan.In the future, it will expand into the broader health industry, using patented TCM as a foundation while actively exploring biopharmaceuticals, internet-based healthcare (mobile healthcare, wearable healthcare, e-commerce, etc.), health supplements, medical devices, and hospitals. As China grows stronger and rises in prominence, Buchang Pharmaceuticals will further deepen its global presence through product acquisitions and corporate mergers, striving toward becoming a company with a market value of hundreds of billions.